The “ABCs” of CVD Reduction in Patients with Type 2 Diabetes
|
The American Diabetes Association recommends that patients with type 2 diabetes (T2D) meet the following “ABC” targets: HbA1c <7%, blood pressure <130/80 mm Hg, and LDL-cholesterol <100 mg/dL. Only 14% of US patients with T2D achieve this 3-factor control. Researchers from the University of Hong Kong conducted a population-based study in 144,000 patients with T2D to determine the relative effects of the ABC factors, individually and in combination, on the CVD prevention. Read more to discover which ABC target was associated with the largest CVD reduction.
|
|
|
|
|
Targeted Nutrition for Dyslipidemia: Practice-Based Research
|
The dyslipidemia epidemic impacts over half of US adults and is a major risk factor for atherosclerotic cardiovascular disease (CVD). Lifestyle interventions, particularly those utilizing medical nutrition therapy, are essential in dyslipidemia management. This multi-site study examined changes in lipids and metabolic syndrome-related variables in 24 overweight patients with dyslipidemia after 4 weeks of daily consumption of a targeted nutrition formula providing macro- and micronutrients.
|
|
Dietary Antioxidants & Parkinson’s Disease Risk
It has been suggested that oxidative stress contributes to the pathogenesis of Parkinson’s disease (PD). Since antioxidants can offset oxidative stress and potentially mitigate neuronal damage associated with PD, researchers from the Karolinska Institutet (Stockholm, Sweden) and University of Southern California investigated the association between habitual intake of dietary antioxidants (β-carotene, vitamin C, and vitamin E) and PD risk later in life in 38,937 women and 45,837 men.
|
|
|
The University of Miami Miller School of Medicine Osher Center for Integrative Medicine
Annual Integrative Medicine Conference 2018
|
|
Sponsored by Metagenics Institute
|
|
Stress, poor nutrition, chronic inflammation, and physiological changes throughout the lifespan can adversely affect cognitive functioning. Optimizing cognitive health outcomes requires personalized, multi-pronged interventions. The Metagenics Institute-sponsored pre-conference features experts in the fields of immunology, neuroscience, gastroenterology, sports medicine and family medicine. Presentations will explore current scientific research and clinical implementation strategies for patient outcomes related to cognitive health. We hope you will join us in Miami!
|
|
Speakers:
Robert Martindale, MD, PhD
Heather Zwickey, PhD
Robert Kachko, ND
Dominic D’Agostino, PhD
Filomena Trindade, MD, MPH
Scott Bergman, DC
|
|
April 26, 2018
8:00 AM – 4:30 PM
1633 N. Bayshore Drive
Miami, FL 33132
|
|
Mark Houston, MD
Thursday, April 12, 2018
11-11:30 AM PT
|
|
In tomorrow’s Metagenics Advanced Practitioner Services (MAPS) talk, Mark Houston, MD will discuss a “Functional Medicine Approach to Dyslipidemia.” Dr. Houston is an internist and cardiovascular specialist, serving as Director of the Hypertension Institute and Vascular Biology at St. Thomas West Hospital. The diagnosis, evaluation, and treatment of dyslipidemia have been misdirected for the past 30-40 years. Dr. Houston challenges the use of LDL-cholesterol and triglycerides as markers of disease and presents an evolutionary approach to dyslipidemia management.
|
|
Follow us on social media!
|
|
Metagenics Institute is a trusted, peer-to-peer, evidence-based educational resource for nutrition and personalized medicine. This center of excellence translates credible research with scientific integrity into innovative clinical decision-making. Metagenics Institute supports a diverse practitioner base to optimize patient outcomes by shifting existing paradigms in healthcare
|
|
|
|
|
|
|